| FENNEC PHARMACEUTICALS |
| Kanada |
| Gesundheit |
| CA31447P1009 / A12A5F |
| RV41 (Frankfurt) / FENC (NASDAQ) |
| FRA:RV41, ETR:RV41, RV41:GR, NASDAQ:FENC |
| - |
| https://fennecpharma.com/ |
|
Fennec Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer. The company's flagship product candidate, Pedmark, is designed to reduce ototoxicity, or he..
>Volltext.. |
| 336.26 Mio. EUR |
| 301.53 Mio. EUR |
| 44.8 Mio. EUR |
| -5.3 Mio. EUR |
| -7.67 Mio. EUR |
| -0.26 EUR |
| - |
| 35.29 Mio. EUR |
| -6.81 Mio. EUR |
| 4.19 |
| 54.48% |
| 41.89% |
| - |
| - |
| - |
| FENNEC |
| 29.06.26 |